Enasidenib (Idhifa)


Indications for Prior Authorization:

  • Treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with isocitrate dehydrogenase-2 (IDH2) positive mutation as detected by an FDA-approved test

All of the following must be met as a condition for coverage:

  • Prescribed by an oncologist, AND
  • Patient is 18 years or older, AND
  • Confirmed presence of IDH2 mutations in the blood or bone marrow


  • 100 mg orally once daily


  • 1 year

Last review date: September 4, 2018

WHA is closely monitoring the Coronavirus Disease 2019 (COVID-19). Learn more about COVID-19.